Reconciliation of movements in equity shareholders' funds ------------------------- Annual report 2000 - contents ------------------------- Financial summary ------------------------- Joint statement by the Chairman & the CEO ------------------------- Description of business ------------------------- Corporate Governance ------------------------- Remuneration Report ------------------------- Operating & Financial Review & Prospects ------------------------- Directors' statements of responsibility ------------------------- Report by the auditors ------------------------- Consolidated statement of profit & loss ------------------------- Consolidated statement of total recognised gains & losses ------------------------- Consolidated statement of cash flow ------------------------- Consolidated balance sheet ------------------------- Reconciliation of movements in equity shareholders' funds ------------------------- Company balance sheet ------------------------- Notes to financial statements ------------------------- Group companies ------------------------- Principal financial statements in US$ ------------------------- Financial record ------------------------- Shareholder Return ------------------------- Taxation information for shareholders ------------------------- Shareholder information ------------------------- Share capital ------------------------- Cross reference to Form 20-F ------------------------- Glossary of terms ------------------------- Contact details
Notes 2000 £m 1999 £m Equity shareholders’ funds at beginning of year   5,464 4,449 Total recognised gains and losses for the year   4,147 2,543 Dividends 15 (2,097) (2,005) Ordinary Shares issued   185 171 Exchange movements on goodwill written off to reserves   10 (29) Goodwill written off to profit and loss account   2 335 Equity shareholders’ funds at end of year   7,711 5,464         Updated March 22, 2001 - © 2001 GlaxoSmithKline - All Rights Reserved Legal Notices - Privacy Statement